Clinical Trials Directory

Trials / Completed

CompletedNCT00626938

Role of Proteomics in Diagnosing Sarcoidosis

Proteomics as a Tool for Biomarker Detection in Sarcoidosis

Status
Completed
Phase
Study type
Observational
Enrollment
1,000 (actual)
Sponsor
Maastricht University Medical Center · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Accepted

Summary

Sarcoidosis is a multi-systemic disorder, meaning that it can involve any organ in the body and that its clinical presentation is highly variable. In 90% of all sarcoidosis cases the lungs are affected. It is difficult to give a concise definition of sarcoidosis due to the fact that its exact cause is still unknown. Consequently, diagnosing the disease is also rather difficult. Up till now, sarcoidosis is generally diagnosed by using general clinical methods to evaluate the status of the lung including a chest X-ray, lung biopsy and bronchoalveolar lavage (BAL). However, some of these methods are considered to be rather invasive and, even more important, non-conclusive. Therefore, the current study has been designed to evaluate the use of a new technique, called SELDI-TOF mass spectrophotometry, for the diagnosis of sarcoidosis. This technique enables the analysis of all enzymes present in the blood of sarcoidosis patients which may hopefully lead to creating a disease-specific protein-profile that may facilitate the recognition of sarcoidosis. Moreover, these results will be compared with other currently used laboratory parameters.

Conditions

Timeline

Start date
2005-03-01
Primary completion
2012-03-01
Completion
2012-03-01
First posted
2008-02-29
Last updated
2012-11-07

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT00626938. Inclusion in this directory is not an endorsement.

Role of Proteomics in Diagnosing Sarcoidosis (NCT00626938) · Clinical Trials Directory